TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06686758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar cane polysaccharide
Description: Sugar cane polysaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar cane polysaccharide
Description: Sugar cane polysaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: placebo
Study: NCT06690515

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A
Description: 0,5 ml DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula A injected three-dose regimen with 28 days interval between doses. Vaccine is injected intramuscularly in left anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B
Description: 0,5 ml injected of DTwP-Hepatitis B-Hib-IPV (Bio Farma) Vaccine Formula B three-dose regimen with 28 days interval between doses. Injected intramuscularly in left anterolateral thigh.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Registered DTwP-Hepatitis B-Hib Vaccine and IPV (Sinovac)®
Description: The control group will receive 0,5 ml of Registered DTwP-Hepatitis B-Hib vaccine and 0,5 ml IPV (Sinovac)® injected in three-dose regimen with 28 days interval between doses. Registered DTwP-Hepatitis B-Hib Vaccine are injected intramuscularly into the left antero-lateral thigh region. IPV (Sinovac)® vaccine are injected intramuscularly into the right mid-lateral thigh region
Study: NCT06691009

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1 (mechanical pleurodesis)
Description: pleural abrasions will be done by scrubbing the parietal and visceral pleura until a uniform aspect of bloody pleura by a piece of gauze attached to the end of a holding forceps , intercostal tube will then placed and monitoring of lung expansion will be done through serial CXR and chest ultrasound follow up and when the lung is fully expanded the tube will be clamped for two hours and follow up CXR will be done for follow up and then the tube removed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 2 chemical pleurodesis by bleomycin)
Description: Those Patients will have indwelling pleural catheter through which pleural fluid will be drained until dryness and then pleurodesis will be done by 60 mg bleomycin dissolved in 50 ml 0.9% saline and 10 ml 2% xylocaine solution then the catheter will be clamped for 6 hours
Study: NCT06687928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P6 SC
Description: A single fixed dose (600 mg) of CT-P6 subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Approved Herceptin SC
Description: A single fixed dose (600 mg) of EU-approved Herceptin subcutaneous
Study: NCT06690957

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga/18F-TATE/JR11/LM3
Description: Each subject receive a single intravenous injection of 68Ga/18F-TATE/JR11/LM3, and undergo PET/CT imaging within the specificed time.
Study: NCT06687369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB12 (Proposed Pembrolizumab Biosimilar)
Description: 200mg IV, every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU-sourced Keytruda®
Description: 200mg IV, every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US-sourced Keytruda®
Description: 200mg IV, every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 IV, every 3 weeks on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV, every 3 weeks on Day 1
Study: NCT05653180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: 200mg IV Q3W
Study: NCT06687369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 IV, every 3 weeks on Day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.
Study: NCT06114108

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
Description: The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
Description: The choice of LAT intervention for the primary tumor and all metastases (surgery or SBRT) and the sequence of the treatment (primary tumor vs metastases) will be decided at the local MDT according to the medical need and patient counseling during interdisciplinary clinic visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy
Study: NCT05214378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finetech-Brindley Sacral Anterior Roots Stimulation System
Description: Electrodes implanted on sacral roots connected to implanted induction coil. External controller box administers stimulation via induction through skin to electrodes. Stimulation activates nerves to modulate bladder, bowel, and sexual functions.
Study: NCT04743518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aortic pulse wave velocity
Description: Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aortic pulse wave velocity
Description: Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aortic pulse wave velocity
Description: Aortic pulse wave velocity (aPWV) is a measure of aortic stiffness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carotid intima media thickness (CIMT)
Description: carotid intima media thickness (CIMT)
Study: NCT06480669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: 8 participants who practiced a 12/12 TRF (12 hours of fasting, from approximately 20:30 to 8:30 the following day).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: A control group consisting of 9 participants who followed a standard Mediterranean diet.
Study: NCT05154747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir, Rilpivirine Drug Combination
Description: Cabotegravir LA 600mg as a 3mL IM injection. The product is packaged in a 3mL USP Type I glass vial. Each vial is for single-dose use. CAB LA injectable suspension is to be stored according to the product label at room temperature (\<30oC). CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol3350, mannitol, and water for injection.~Rilpivirine LA 900mg as a 3mL IM injection. Each single-dose vial contains 900mg/3mL rilpivirine. RPV LA injectable suspension should be stored according to the product label refrigerated at 2-8oC and should be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, and water for injection.~Cabotegravir Long-Acting (CAB LA) will be given IM into one buttock, and Rilpivirine Long-Acting (RPV LA) will be given IM into the opposite buttock.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TLD
Description: Dolutegravir 50mg oral with tenofovir disoproxil fumarate (245mg) and lamivudine (300mg) in a fixed dose combination or Dolutegravir 50mg oral with tenofovir alafenamide fumarate (25mg) and lamivudine (300mg) (l/TAF) oral in a fixed dose combination
Study: NCT04548661

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative incisional wound irrigation with povidone-iodine solution
Description: Participants randomized to the povidone-iodine irrigation group will have all incisions irrigated once with povidone-iodine diluted in 0.9% sterile normal saline (to a final concentration of 5% povidone-iodine (0.5% available iodine)) delivered through a bulb syringe. The povidone-iodine irrigation should be left on for 60 seconds and then dried with sterile gauze. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
Study: NCT06687369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 5 IV, every 3 weeks on Day 1 for 4 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
Study: NCT04548661

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intraoperative incisional wound irrigation with saline
Description: Participants randomized to the saline irrigation group will have all incisions irrigated once with 0.9% sterile normal saline delivered through a bulb syringe. Irrigation will be performed after any/all deep tissue layers are closed, prior to skin closure. The volume used will be left to the discretion of the clinician and irrigation will be administered until saturation is achieved.
Study: NCT05339464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Wellness program
Description: Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Wellness program
Description: Weekly one-hour online workshops over an 8 week period. Families will also receive text message reminders as part of the intervention.
Study: NCT05945485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVC H1 HA mRNA vaccine
Description: A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery
Study: NCT04743518

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carotid intima media thickness (CIMT)
Description: carotid intima media thickness (CIMT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carotid intima media thickness (CIMT)
Description: carotid intima media thickness (CIMT)
Study: NCT05146024

Intervention type: BEHAVIORAL
Intervention: Way To Serve Plus: Improving Responsible Alcohol Service
Description: Improving responsible alcohol service of owners, managers, and employees of alcohol-serving establishments by developing professional development components to enhance their responsible beverage service skills.
Study: NCT05556005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimetazidine Dihydrochloride
Description: Trimetazidine Dihydrochloride 35 mg modified release tablet used twice daily
Study: NCT05945485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVC H1 HA mRNA vaccine
Description: A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCVC H1 HA mRNA vaccine
Description: A modified nucleoside messenger RNA (mRNA) vaccine encoding the full length HA of influenza A/California/07/2009 (H1N1) encapsulated in lipid nanoparticle (LNP) composed of ionizable lipid, DSPC, cholesterol, and PEG lipid for delivery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Recombinant Seasonal Influenza Vaccine
Description: The vaccine contains recombinant hemagglutinin (HA) proteins from four influenza viruses, expressed using a baculovirus vector. These HA proteins are produced in a continuous insect cell line.
Study: NCT05556005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch tablets used twice daily
Study: NCT05430815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Postpartum Care System
Description: The intervention consists of a comprehensive postpartum care system that integrates American College of Obstetrician and Gynecologist's (ACOG) postpartum care guidelines together with American College of Cardiology and American Heart Association (ACC/AHA) guidelines for the prevention of cardiovascular disease in women, as well as patient preferences for care coordination and communication. The system consists of: 1) a tailored postpartum care plan that is collaboratively developed with patient and provider input and addresses both social and medical needs; 2) an electronic medical record (EMR) based tool for documenting the plan and monitoring postpartum care; and 3) a postpartum follow-up phone call at 1 week postpartum.
Study: NCT05945485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Chloride, 0.9%
Description: 0.9% Sodium Chloride Injection
Study: NCT06644560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Intervention
Description: The intervention involves a 3-week prehabilitation program during the participant's preoperative window before cancer surgery. During the intervention, patients will be asked to consume 60 grams of walnuts daily, participate in two 60-minute individualized supervised physical activity training sessions per week, meet with a nutritionist for a 30-60 minute session, and conduct 30 minutes of independent walking per day. The participants will be given pre-portioned walnuts for daily consumption, a pedometer, and educational materials. The participants will track their completion of tasks with a daily log and the study coordinator will also track their attendance at scheduled nutrition and fitness sessions. In addition, the study coordinator will check-in with participants twice weekly and send text reminders about their required activities.
Study: NCT05951153

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tributyrin
Description: Tributyrin is a nutritional supplement prepared by esterification of glycerin with butyric acid that promotes delivery of free butyrate to distal portions of the gut.
Study: NCT06687369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 IV, every 3 weeks on Day 1 for 4 cycles
Study: NCT06686550

Intervention type: OTHER
Intervention: This is a observational study and there is no intervention.
Description: This is a observational study and there is no intervention.
Study: NCT06688526

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quiet Sounds
Description: Quiet sounds are played during sleep

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham sounds
Description: No sounds are played during sleep
Study: NCT06687486

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxin
Description: caregivers relaxing and care burden

Intervention type: OTHER
Group type: OTHER
Intervention: kontrol
Description: no intervention
Study: NCT06691139

Intervention type: PROCEDURE
Intervention: Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years
Description: Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia

Intervention type: PROCEDURE
Intervention: Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia graft in patients ages from 12 years to 40 years
Description: Myringoplasty using periosteal graft and myringoplasty using Temporalis fascia

Intervention type: OTHER
Intervention: Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft
Description: Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft

Intervention type: OTHER
Intervention: Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft
Description: Group (A) Myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft

Intervention type: PROCEDURE
Intervention: Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft
Description: Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years

Intervention type: PROCEDURE
Intervention: Myringoplasty operation using periosteal graft and myringoplasty using Temporalis fascia graft
Description: Myringoplasty using Temporalis fascia graft and myringoplasty using periosteal graft in age from 12years to 40 years

Intervention type: PROCEDURE
Intervention: Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
Description: Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years

Intervention type: PROCEDURE
Intervention: Group (A) myringoplasty using periosteal graft Group (B) Myringoplasty using Temporalis fascia graft
Description: Myringoplasty operation using Temporalis fascia graft and Myringoplasty using periosteal graft in patients from 12 years to 40 years
Study: NCT06689514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha receptor antagonist
Description: Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha receptor antagonist
Description: Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha receptor antagonist
Description: Oral administration of alpha receptor antagonist (according to the dosage specified in the instructions for treating BPH)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Tranilast
Description: Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 100mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Tranilast
Description: Oral administration of Tranilast Capsules (Qu Ke Shen, Yao Da Pharmaceutical) 200mg TID
Study: NCT06686290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Technique
Description: Post isometric relaxation will be performed with the frequency of 5 times, such that it includes 30 isometric contraction of the muscle to be stretched for 10 seconds, followed by rest period of 5 seconds and then a stretch of 10 seconds hold.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Static Stretching
Study: NCT06686277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gong's Mobilization Technique
Description: The therapist will push the scapula of the affected side in a posterior to anterior direction with one hand, and pushed the humeral head in an anterior to posterior direction parallel to joint plane with the other hand.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization Technique
Description: Mulligan Mobilization Technique
Study: NCT06694727

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 100 Milligrams Oral Capsule
Description: 100 mg capsules given twice daily, per oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Coenzyme Q10 100 Milligrams Oral Capsule
Description: 100 mg capsules given twice daily, per oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium 100 Micrograms Oral Tablets
Description: 100 μg tablets given twice daily, per oral use.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium 100 Micrograms Oral Tablets
Description: 100 μg tablets given twice daily, per oral use.
Study: NCT06691425

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: SBRT (5 x 8 Gy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard of care: mFOLFIRINOX or gemcitabine/nab-paclitaxel
Study: NCT06687746

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Intervention type: DEVICE
Intervention: Bili-ruler
Description: The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.
Study: NCT06688097

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compression of esophageal
Description: Before the start of FMV, ultrasound is used to locate the esophagus, and pressure is applied to the esophagus at the cricoid level to collapse the esophageal lumen. Esophageal pressure is released just before tracheal intubation following 4 minutes of ventilation.